Prognostication tool for myeloma patients based on the genetics and other routinely used lab values in conjunction with the original ISS Staging System. Use only in patients recently diagnosed with multiple myeloma. Do not use in patients with relapsed myeloma, smoldering myeloma or MGUS.

Staging for multiple myeloma is based largely on the results of tests that have been done. The stage helps doctors describe how much cancer is in the body. It helps determine how serious the myeloma is and how best to treat it. Doctors also use the …

The ISS and R-ISS are the latest prognostic staging systems for multiple myeloma. Learn more about their significance and access detailed information.

The Revised International Staging System (R-ISS) includes variables included in the original ISS (serum beta-2 microglobulin and serum albumin), while also including the additional prognostic information obtained from serum LDH and high-risk chromosomal abnormalities detected by interphase fluorescent in situ hybridization (iFISH) after CD138 pl...

Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion. Zhao Y, Zhou FJ Cancer Res Clin Oncol 2023 Mar;149 (3):995-1006. Epub 2022 Feb 25 doi: 10.1007/s00432-022-03948-9. PMID: 35212816.

R-ISS-3 includes patients with ISS-3 (serum β 2 -microglobulin level >5.5 mg/L) and either high-risk cytogenetic abnormalities in iFISH or elevated LDH levels.

May 13, 2024 · RISS Stage Group III: Serum beta-2 microglobulin is 5.5 (mg/L) or greater, cytogenetics are considered “high-risk” (meaning there is at least one kind of change to chromosomes 17, 4, 14, or 16), and LDH levels are high. How is multiple myeloma treated?

Jan 6, 2023 · Doctors stage multiple myeloma using either the Durie-Salmon Staging System or the Revised International Staging System (RISS). Multiple myeloma stages range from 0 to 3, with 3 being the...

mSMART 3.0: Classification of Active MM High Risk genetic Abnormalities a,b t(4;14) t(14;16) t(14;20) Del 17p p53 mutation Gain 1q RISS Stage 3 High Plasma Cell S-phasec GEP: High risk signature All others including: Trisomies dt(11;14) t(6;14) High-Risk Standard-Riska aTrisomies may ameliorate b By FISH or equivalent method

May 20, 2016 · Conclusions: The RISS combines the prognostic power of high risk CA and LDH with ISS score and gives a better differentiation of MM patients into 3 survival subgroups. It should be used to stratify patients in future clinical trials to …